Study finds no increased risk of autism spectrum disorder with maternal topiramate use in pregnancy

A large population-based cohort study using data from US healthcare utilisation databases (Medicaid and MarketScan) suggests that topiramate use in pregnancy may not be associated with an increased risk of autism. More information is available here, This finding contrasts with a 2022 study which suggested an almost 3-fold increased risk following in utero topiramate exposure. A helpful overview of these studies is provided in an NEJM editorial which is available here.